FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer
The U.S. Food and Drug Administration (FDA) approved the non-radioactive tracer Magtrace for the pre-surgical detection of lymph nodes affected by breast cancer. Used in combination with Sentimag Magnetic Localization System, Magtrace allows surgeons to determine which lymph nodes might be affected by breast cancer cells. Doctors collect a biopsy from those nodes to look for signs of cancer before a patient undergoes breast cancer surgery. “We’ve been watching this technology become established in Europe over the past few years, and have been eagerly awaiting its availability in the US,” Michael Alvarado, professor of surgery at The University of California, San Francisco, said in a news release. “After 18 months of using the Sentimag platform with Magseed for lesion localization, we’re really excited to add the sentinel node biopsy capability with Magtrace,” Alvarado said. The typical treatment for breast cancer is to surgically remove the tumor and determine whether the cancer has spread. For that, clinicians must map the neighboring lymph nodes and determine which are connected to the tumor. This requires the use of  radioactive drugs and blue dyes. Magtrace is a non-radioactive liquid marker designed by Endomag to reveal the route cancer cells are most likely to take when spreading from the primary tumor site. It is a dark solution of tiny iron particles coated with a sugar-like compound (carboxydextran). Unlike other available tracers, Magtrace can be injected into the breast tissue up to a week before surgery, and can be detected just 20 minutes after administration. This is because of its size: small enough to be quickly absorbed, but big enough to be retained in the lymph nodes. By placing Sentimag — a handheld magnetic probe
Subscribe or to access all post and page content.